Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has turned decades of RNA research into its first independently launched neurology medicine. The FDA-approved Zanvastro, chemically known as zilganersen, for adults and children with Alexander disease, has taken the lead as the first approved disease-modifying treatment for the rare neurological disorder.
Ionis has set a price of $285,000 per dose and expects Zanvastro to generate more than $100 million in peak annual sales. The approval opens a new commercial opportunity, but the drug's high price, invasive administration, and extremely small patient population will make access and execution critical.
Zanvastro enters a market with no previously approved treatment capable of modifying the underlying disease. Alexander disease is a progressive and often fatal genetic disorder that damages the nervous system and can impair movement, speech, swallowing, and cognitive function. It affects fewer than 1,000 people in the United States, according to National Institutes of Health data cited by Reuters.
The FDA based its decision on a Phase 1–3 study involving 54 participants between 1.5 and 53 years old. Among patients aged five and older, the approved 50 mg dose produced statistically significant and clinically meaningful stabilization in gait speed, measured using a 10-meter walk test at Week 61. The least-squares mean difference from the control group was 33.3%, with a p-value of 0.041, and younger patients aged two to four also showed improvement in gross motor function compared with controls.
Commercially, the ultra-rare population means Ionis (NASDAQ:IONS) does not need thousands of patients to reach its peak-sales forecast. Zanvastro is administered once every three months, implying four doses and approximately $1.14 million in annual list-price cost for a full year of treatment before discounts, insurance coverage, or patient assistance. The approval may also have implications beyond Zanvastro. Oppenheimer analyst Jay Olson believes it meaningfully reduces perceived risk around Ionis' wider neurology pipeline, including obudanersen for Angelman syndrome, for which late-stage results are expected in the second half of 2027.
Zanvastro's commercial opportunity is constrained by the rarity of Alexander disease. Finding eligible patients, securing reimbursement, and coordinating treatment through specialist centers could make adoption gradual. Ionis (NASDAQ:IONS) expects the drug to become available in the United States in the coming weeks, but it has not disclosed launch-year sales guidance. The $285,000 price applies to each dose rather than a full year of therapy. An implied annual list cost of approximately $1.14 million could create reimbursement and affordability challenges, even though realized net revenue per patient will likely be lower after discounts and other adjustments.
Administration is another hurdle. Zanvastro must be injected into the spinal canal by a healthcare professional every three months. Its prescribing information also includes a warning concerning aseptic meningitis. The most common adverse reactions included vomiting, back pain, cough, headache, and post-lumbar-puncture syndrome. Finally, one approval cannot establish that Ionis' (NASDAQ:IONS) other neurological candidates will succeed. Obudanersen targets a different disease, and its efficacy and safety must be demonstrated independently.
Zanvastro gives Ionis (NASDAQ:IONS) a commercially meaningful first in an ultra-rare disease and validates its ability to bring an independently developed neurology medicine through FDA review. The trial results and absence of an existing disease-modifying treatment support the launch.
Its ultimate value, however, will depend on patient identification, reimbursement, and sustained access. The approval strengthens Ionis' (NASDAQ:IONS) neurology story, but the $100 million-plus peak-sales ambition still requires disciplined commercial execution.
While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.